Cancer drug developer Calithera lands Series D round of $35 million
October 29, 2013 at 13:40 PM EDT
Calithera BioSciences Inc. scooped up a $35 million Series D round, allowing it to push into a Phase I trial testing its lead experimental drug against advanced solid tumors...
